Maxygen other news

Maxygen said HHS's Biomedical Advanced Research and Development Authority (BARDA) rejected a proposal for MAXY-G34 to treat acute radiation syndrome (ARS). Maxygen said BARDA found its proposal "technically sound" but raised concerns about the dependence on overseas manufacturing, uncertain IP issues for MAXY-G34 and the company's reliance on consultants and subcontractors. Maxygen said it will evaluate its plans for the compound in ARS. MAXY-G34, a pegylated G-CSF, completed a Phase IIa trial for chemotherapy-induced neutropenia (CIN). Details were not disclosed. ...